ASF 1097

Drug Profile

ASF 1097

Alternative Names: ASF-1097

Latest Information Update: 08 Jul 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astion Pharma A/S
  • Class Anti-inflammatories; Antiacnes
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Acne vulgaris

Most Recent Events

  • 08 Jul 2011 No development reported - Phase-I for Acne vulgaris in Denmark (Topical)
  • 23 Jan 2007 Phase-I clinical trials in Acne vulgaris in Denmark (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top